BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 16, 2025
Home » Authors » Gina Lee

Articles by Gina Lee

Inserting contact lens into eye

New smart contact lens may diagnose, treat diabetes more comfortably

March 17, 2022
By Gina Lee
A smart contacts lens that detects diabetes and treats diabetic retinopathy could provide patients with a more comfortable alternative to insulin shots and monitoring blood glucose levels. The product was developed by a research team at the Pohang University of Science & Technology (POSTECH) that includes Sei Kwang Hahn, the CEO of Seoul, South Korea-based Phi Biomed Co. Ltd.
Read More
James Jungkue Lee, CEO, Bridge Biotherapeutics

Bridge Biotherapeutics secures second IPF candidate, targets IND by late 2022

March 15, 2022
By Gina Lee

Bridge Biotherapeutics Inc. has signed an exclusive option-to-license agreement for Cellionbiomed Inc.’s preclinical ion channel modulator, BBT-301, thus adding a second idiopathic pulmonary fibrosis (IPF) candidate to its fibrotic diseases portfolio. The company hopes to enter the clinic with the drug in the U.S. by the end of 2022.


Read More

Nec acquires Vaximm assets for personalized T-cell cancer vaccines

March 15, 2022
By David Ho and Gina Lee

Nec Corp. has acquired all of Vaximm AG’s neoantigen program assets. Tokyo-based Nec will conduct the acquisition via its subsidiary, Nec Oncoimmunity AS.


Read More
south-korea-flag-asia.png

Everest Medicines expands IgAN deal with Calliditas to include South Korea

March 15, 2022
By Gina Lee
Everest Medicines Ltd. has acquired rights to develop and commercialize Nefecon (budesonide) for the treatment of primary IgA nephropathy in South Korea from Calliditas Therapeutics AB.
Read More

SEC identifies firms for tougher audits, including three biopharmas

March 15, 2022
By Gina Lee
The U.S. Securities and Exchange Commission (SEC) recently issued a provisional list of five U.S.-listed Chinese companies that reportedly failed to submit necessary accounting reports required under Holding Foreign Companies Accountable Act. The list included three biopharmas: Beigene Ltd., Hutchmed Ltd., and Zai Lab Ltd.
Read More

SEC identifies firms for tougher audits, including three biopharmas

March 14, 2022
By Gina Lee
The U.S. Securities and Exchange Commission (SEC) recently issued a provisional list of five U.S.-listed Chinese companies that reportedly failed to submit necessary accounting reports required under Holding Foreign Companies Accountable Act. The list included three biopharmas: Beigene Ltd., Hutchmed Ltd., and Zai Lab Ltd.
Read More
Rocket launch illustration

Korean med-tech startups get a boost via Shinhan’s program

March 10, 2022
By Gina Lee
Med-tech startups looking to enter the South Korean market might do so with the 2021 Global Inbound Membership Bridge to Korea, or B2K 2021 program, run by Shinhan Financial Group Co. Ltd.’s Shinhan Square Bridge Incheon. The organization fosters startups with business scale-up services, new market development, partnering and investment assistance. Six med-tech and digital health firms were selected in November 2021: Aevice Health Pte. Ltd., Fairphonic Pte. Ltd., NDR Medical Technology Pte. Ltd., Scanderm Pro LLC, Sqin and Vertliner Private Co.
Read More

Nec acquires Vaximm assets for personalized T-cell cancer vaccines

March 10, 2022
By David Ho and Gina Lee

Nec Corp. has acquired all of Vaximm AG’s neoantigen program assets. Tokyo-based Nec will conduct the acquisition via its subsidiary, Nec Oncoimmunity AS.


Read More
James Jungkue Lee, CEO, Bridge Biotherapeutics

Bridge Biotherapeutics secures second IPF candidate, targets US FDA IND by late 2022

March 10, 2022
By Gina Lee

Bridge Biotherapeutics Inc. has signed an exclusive option-to-license agreement for Cellionbiomed Inc.’s preclinical ion channel modulator, BBT-301, thus adding a second idiopathic pulmonary fibrosis (IPF) candidate to its fibrotic diseases portfolio. The company hopes to enter the clinic with the drug in the U.S. by the end of 2022.


Read More

Shionogi aims for Japan’s first conditional approval for COVID-19 treatment

March 8, 2022
By Gina Lee

Shionogi and Co. Ltd. is looking to become the first company to get approval for a COVID-19 treatment under Japan’s conditional approval system as it prepares a phase III trial for S-217622 (ensitrelvir), its oral antiviral drug for COVID-19. 


Read More
Previous 1 2 3 4 5 6 7 8 9 … 38 39 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 16, 2025.
  • Art concept for bladder

    Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

    BioWorld
    During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing